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Abstract
In order to test the hypothesis (Munn, Zhou, Attwood, Bondarev, Conway, Marshall, Brown, Mellor, Science 281 (1998)
1191^1193) that localized placental tryptophan catabolism prevents immune rejection of the mammalian fetus, the cellular
localization and characteristics of human placental indoleamine 2,3-dioxygenase (EC 1.13.11.42) were studied. The
localization of indoleamine 2,3-dioxygenase activity was determined quantitatively using cell fractionation by differential and
discontinuous sucrose gradient centrifugation. Enzyme activity was looked for in isolated brush border microvillous plasma
membranes of placental syncytiotrophoblast. We found that this membrane preparation (which showed a 32.4-fold
purification from the starting homogenate with reference to the activity of a membrane marker enzyme, alkaline phosphatase
(EC 3.1.3.1)) was strongly negatively enriched with indoleamine 2,3-dioxygenase (which showed a one twenty-fifth decrease
in its specific activity). Placental indoleamine 2,3-dioxygenase is thus not expressed in the maternal facing brush border
membrane of syncytiotrophoblast. 1-Methyl-DL-tryptophan which was used by Munn et al. as a key experimental tool for
inhibiting indoleamine 2,3-dioxygenase in the murine model showed a competitive inhibition of human placental indoleamine
2,3-dioxygenase with L-tryptophan. The hypothesis, based on experiments performed in mouse, may therefore be applicable
to avoidance of immune rejection of the fetus in human pregnancy. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Indoleamine 2,3-dioxygenase is a heme-containing
protein that catalyzes the oxidative cleavage of the
pyrrole ring of the indole nucleus of various indole-
amines upon the insertion of two oxygen atoms of
molecular oxygen [1]. Previous studies have shown
that indoleamine 2,3-dioxygenase activity is relatively
highly expressed in the lung, small intestine and pla-
centa of mammals such as rabbits [2], rats [3], mice
[4] and humans [5]. Although the precise physiolog-
ical role of indoleamine 2,3-dioxygenase is still un-
known, the enzyme is induced under pathological
conditions including virus infection [6], parasitic
infestation [7] and tumor transplantation into allo-
genic animals [8,9]. Interferon-Q, which exerts potent
immunomodulatory and antiproliferative e¡ects,
strongly induces the expression of genes coding for
indoleamine 2,3-dioxygenase [10]. Therefore the anti-
proliferative e¡ect of interferon-Q on tumor cells and
the inhibitory e¡ect on intracellular pathogens are at
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least partly attributable to the depletion of the essen-
tial amino acid, L-tryptophan, through the induction
of indoleamine 2,3-dioxygenase. With regard to its
role in normal pregnancy, Munn et al. [11] have re-
cently proposed the hypothesis that the expression of
this enzyme in the placenta is crucial to prevention of
immunological rejection of the fetal allograft. They
administered 1-methyl-tryptophan, a pharmacologic
inhibitor of intestinal indoleamine 2,3-dioxygenase
[12], to pregnant mice and found a rapid T cell-in-
duced rejection of allogenic concepti. They suggested
that the mechanism of T cell inhibition involves in-
doleamine 2,3-dioxygenase-dependent localized de-
pletion of L-tryptophan at the site of placentation.
We therefore investigated a key feature of the human
placental enzyme in an attempt to extend the ¢ndings
of Munn et al. [11] to human pregnancy. In the hu-
man, is placental indoleamine 2,3-dioxygenase a cy-
toplasmic or a cell surface enzyme? This has not
been studied previously.
We have also addressed the question of whether in
the human as in the mouse, the enzyme is inhibited
by 1-methyl-tryptophan.
2. Materials and methods
2.1. Materials
L-Tryptophan, 1-methyl-DL-tryptophan, L-kynure-
nine, norharman, indo-3-acetamide, L-indolylaceto-
nitrile, 3-L-indoleacrylic acid, p-dimethylaminoben-
zaldehyde and bovine liver catalase were purchased
from Sigma (Poole, Dorset, UK). All other chemicals
were of the highest purity commercially available.
2.2. Preparation of indoleamine 2,3-dioxygenase from
placenta
For normal measurement of placental indoleamine
2,3-dioxygenase activity the enzyme was prepared
from term placenta as follows. The fetal membrane
was removed, the placenta was cut into cotyledons
and the decidual surface was removed. The villous
tissue was washed and homogenized in 3 vols. of ice-
cold 250 mM sucrose containing 50 mM Tris-
HEPES bu¡er (pH 7.5) and 0.2 mM EDTA. Homog-
enization was performed ¢rstly using a Waring blen-
der operated for 3 min and secondly using a Potter-
Elvehjem homogenizer for ten strokes. The suspen-
sion was ¢ltered through three layers of cotton
gauze. The ¢ltrate was then centrifuged for 30 min
at 10 000Ug. The supernatant was collected and
stored 320‡C until used.
2.3. Assay of indoleamine 2,3-dioxygenase
Indoleamine 2,3-dioxygenase activity was deter-
mined colorimetrically by a modi¢ed procedure of
the method of Takikawa et al. [13]. The reaction
was initiated by adding 0.5 ml of the enzyme suspen-
sion (approx. 2 mg of protein) to 0.5 ml of the in-
cubation medium composed of 0.8 mM L-trypto-
phan, 40 mM ascorbic acid, 20 WM methylene blue,
200 units/ml catalase and 100 mM potassium phos-
phate bu¡er (pH 6.5). Other additions are described
in the legend to Fig. 2. Both the enzyme suspension
and the incubation medium were preincubated inde-
pendently at 37‡C for 5 min before mixing, followed
by further incubation at 37‡C for 30 min. The reac-
tion was terminated by adding 0.2 ml of 30% (w/v)
trichloroacetic acid, and further incubated at 50‡C
for 30 min to hydrolyze N-formylkynurenine pro-
duced by indoleamine 2,3-dioxygenase to kynure-
nine. The reaction mixture was then centrifuged for
20 min at 3000Ug to remove sediment. 0.8 ml of the
supernatant was collected and then 0.8 ml of 1%
(w/v) p-dimethylaminobenzaldehyde in acetic acid
was added. The absorbance at 480 nm for the yellow
color derived from kynurenine was determined.
2.4. Subcellular fractionation of
indoleamine 2,3-dioxygenase
Subcellular fractionation of human placental indo-
leamine was performed from freshly obtained normal
term placenta according to the standard method for
preparing brush border membrane of syncytiotro-
phoblasts [14].
2.5. Analytical measurements
Alkaline phosphatase activity was determined by a
previously established procedure [15]. Protein con-
centration was determined by the method of Lowry
et al. [16] using bovine serum albumin as a standard.
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3. Results and discussion
In order to investigate the cellular localization of
indoleamine 2,3-dioxygenase, we carried out subcel-
lular fractionation to determine whether the placen-
tal isoform of this enzyme is membrane bound or
cytoplasmic. The isolation procedure of apical (brush
border) membrane of placental syncytiotrophoblasts
(facing towards the maternal circulation) is schemati-
cally illustrated in Fig. 1. By applying the crude
brush border membrane fraction (Ppt 2) to a discon-
tinuous sucrose gradient centrifugation further puri-
¢cation of the membrane fraction (Int 2) was ob-
tained (cf. Kelley et al. [17]). That this puri¢ed
membrane preparation contains multiple transport
systems for various amino acids expressed at the ma-
ternal face of the syncytiotrophoblast has been con-
¢rmed [14,18]. Table 1 summarizes the activities of
indoleamine 2,3-dioxygenase and alkaline phospha-
tase (a marker enzyme of the brush border mem-
brane) at each stage of the isolation procedure shown
in Fig. 1. The crude (Ppt 2) and puri¢ed (Int 2)
membrane preparation showed a degree of alkaline
phosphatase enrichment 13.5 and 32.4 times greater
than that of the villous tissue homogenate. While
indoleamine 2,3-dioxygenase showed an enrichment
in cytoplasmic fraction (Sup 3) and one sixth and
one twenty-¢fth decrease in its speci¢c activity in
Ppt 2 and Int 2. These results indicate that the pla-
cental isoform of indoleamine 2,3-dioxygenase is not
expressed at the brush border membrane of the syn-
cytiotrophoblast but is a cytoplasmic enzyme and
that L-tryptophan therefore has to enter the cell in
order to be catabolized by this enzyme. It is possible
to speculate that transmembrane transport may reg-
Fig. 1. Schematic representation of isolation of placental brush
border membrane. Sup, supernatant; Ppt, pellet ; Int, interface.
Table 1
Indoleamine 2,3-dioxygenase and alkaline phosphatase activity during brush border membrane isolation
Sample Indoleamine 2,3-dioxygenase Alkaline phosphatase
Speci¢c activity
(nmol/min per mg)
Yield
(%)
Puri¢cation
(fold)
Speci¢c activity
(Wmol/min per mg)
Yield
(%)
Puri¢cation
(fold)
Homogenate 0.124 þ 0.003 100 1 0.901 þ 0.005 100 1
Sup 1 0.238 þ 0.005 111 1.91 1.335 þ 0.039 87.3 1.50
Sup 2 0.374 þ 0.008 112 3.01 1.723 þ 0.062 71.7 1.91
Ppt 1 0.024 þ 0.001 2.90 0.19 1.266 þ 0.032 21.2 1.40
Sup 3 0.598 þ 0.005 149 4.81 0.914 þ 0.047 31.5 1.01
Ppt 2 0.019 þ 0.001 0.37 0.15 12.200 þ 0.269 33.6 13.52
Int 1 0.085 þ 0.001 0.14 0.68 0.981 þ 0.050 0.2 1.09
Int 2 0.005 þ 0.004 0.02 0.04 29.252 þ 0.497 13.9 32.44
Int 3 0.003 þ 0.003 0.01 0.02 5.955 þ 0.309 2.6 6.60
Activities were determined as described in the text. Values are mean þ S.D. for speci¢c activity and mean for yield and puri¢cation.
Samples correspond to stages as shown in Fig. 1. Sup, supernatant; Ppt, pellet ; Int, interface.
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ulate the extent of L-tryptophan catabolism and
hence the mechanism responsible for the suppression
of the maternal immune response to allogenic con-
ceptus [11].
We then characterized placental indoleamine 2,3-
dioxygenase. As previously reported by Yamazaki et
al. [5], the enzyme required a reducing system, ascor-
bic acid and methylene blue, for the catalytic activity.
The maximal activity of indoleamine 2,3-dioxygenase
was observed at 10 mM ascorbic acid and 5 WM
methylene blue (data not shown). Catalase at a con-
centration of 100 units/ml was also required for
maximal enzyme activity to escape the inhibitory
e¡ect of hydrogen peroxide produced by the reducing
system (i.e. ascorbic acid and methylene blue) as a
result of reduction of oxygen [19]. The placental iso-
form of indoleamine 2,3-dioxygenase oxidizes L-tryp-
tophan preferentially with a pH optimum of 6.5.
However, the enzyme had a broad substrate speci¢c-
ity and was able to react with D-tryptophan, 5-hy-
droxy-L-tryptophan, tryptamine and 5-hydroxytrypt-
amine. The rate of N-formylkynurenine formation
as a function of L-tryptophan concentration showed
saturable hyperbolic curves that obeyed Michaelis-
Menten kinetics (data not shown). The calculated
values of the Michaelis constant, Km, and maximum
velocity, Vmax, for L-tryptophan were 24.6 WM and
0.51 nmol/min per mg of protein, respectively.
1-Methyl-DL-tryptophan which was used by Munn
et al. [11] as a key experimental tool for inhibiting
indoleamine 2,3-dioxygenase activity in the pregnant
mouse has been reported to be a competitive inhib-
itor for the rabbit intestinal isoform of the enzyme;
no report has yet appeared concerning its e¡ect on
human placental indoleamine 2,3-dioxygenase. We
therefore investigated the e¡ect of 1-methyl-DL-tryp-
tophan on human placental indoleamine 2,3-dioxyge-
nase and also the e¡ect of norharman and indole
derivatives (indo-3-acetamide, L-indolylacetonitrile,
3-L-indoleacrylic acid) which potently inhibit intesti-
nal indoleamine 2,3-dioxygenase and hepatic trypto-
phan 2,3-dioxygenase (EC 1.13.11.11), respectively
[19]. Among these compounds at the concentration
of 2 mM, 1-methyl-DL-tryptophan (70%) and norhar-
man (98%) showed marked inhibition of human pla-
cental indoleamine 2,3-dioxygenase activity, while in-
dole derivatives tested had no inhibitory e¡ect. None
of these compounds were found to serve as sub-
strates for placental indoleamine 2,3-dioxygenase
(data not shown). Kinetic studies were then per-
formed using either 1-methyl-DL-tryptophan (Fig.
2A) or norharman (Fig. 2B). The apparent values
Fig. 2. E¡ect of 1-methyl-DL-tryptophan (A) and norharman
(B) on the placental indoleamine 2,3-dioxygenase activity. The
rate of formation of the product catalyzed by indoleamine 2,3-
dioxygenase was determined in a medium containing varying
concentrations of either 1-methyl-DL-tryptophan (A) or norhar-
man (B), 20 mM ascorbic acid, 10 WM methylene blue,
100 units/ml catalase and 50 mM potassium phosphate bu¡er
(pH 6.5) in the presence of indicated concentrations of L-trypto-
phan. 1-Methyl-DL-tryptophan: b, 0 WM; a, 40 WM; S,
200 WM; P, 400 WM. Norharman: b, 0 WM; a, 100 WM; S,
200 WM; P, 500 WM. Each point represents the mean þ S.D.
for triplicate experiments. The nature of the inhibition by
1-methyl-DL-tryptophan is competitive, and that by norharman
is uncompetitive (see text).
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of Km (WM) and Vmax (nmol/min per mg of protein)
calculated were, respectively: in the presence of
1-methyl-DL-tryptophan at a concentration of 0 WM,
24.2 and 0.42; 40 WM, 33.7 and 0.41; 200 WM, 93.3
and 0.40; 400 WM, 155.6 and 0.39, in the presence of
norharman at a concentration of 0 WM, 25.5 and
0.46; 100 WM, 23.8 and 0.35; 200 WM, 19.0 and
0.22; 500 WM, 10.5 and 0.11. These results showed
that 1-methyl-DL-tryptophan was competitive and
norharman was uncompetitive with L-tryptophan
for human placental indoleamine 2,3-dioxygenase.
The Ki values giving half-maximal inhibition for
L-tryptophan determined by replotting for the appa-
rent Km values against the inhibitor concentrations
were found to be 68 WM for 1-methyl-DL-tryptophan
and 176 WM for norharman. The pattern of inhibi-
tion by norharman with L-tryptophan has been
reported to be uncompetitive for rabbit intestinal
indoleamine 2,3-dioxygenase and competitive for
mouse hepatic tryptophan 2,3-dioxygenase [20].
(Sono and Cady [21] reported, however, noncompe-
titive inhibition of indoleamine 2,3-dioxygenase by
norharman.) The abortifacient action of some L-car-
boline derivatives in rats has been reported [22]; this
e¡ect we suggest may be attributed to the inhibition
of indoleamine 2,3-dioxygenase by L-carboline deriv-
atives. Interestingly, norharman has been found to
be a normal constituent of human blood albeit at
very low concentrations [23].
Since the assumption that 1-methyl-DL-tryptophan
possesses an inhibitory e¡ect on human placental
indoleamine 2,3-dioxygenase has now been con-
¢rmed, Munn et al.’s hypothesis may therefore be
applicable to human pregnancy. In order to clarify
more precisely the physiological signi¢cance of pla-
cental indoleamine 2,3-dioxygenase, we aim to inves-
tigate: (1) transport of L-tryptophan and its under-
lying regulatory mechanism in the placental
syncytiotrophoblast (since indoleamine 2,3-dioxyge-
nase is cytoplasmic, L-tryptophan must enter the syn-
cytiotrophoblast in order for the enzyme to have its
e¡ect); (2) regulation of placental indoleamine 2,3-
dioxygenase expression by cytokines as observed pre-
viously in various other types of cell ; (3) comparison
of the levels of indoleamine 2,3-dioxygenase expres-
sion between normal and abnormal pregnancy such
as recurrent miscarriage and preeclampsia.
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